EXACT Sciences Co. (NASDAQ:EXAS) has earned a consensus recommendation of “Buy” from the fifteen ratings firms that are covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation, ten have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $87.20.

EXAS has been the subject of several research reports. Cowen lifted their target price on EXACT Sciences from $65.00 to $85.00 and gave the stock an “outperform” rating in a research report on Monday, June 18th. BidaskClub downgraded EXACT Sciences from a “strong-buy” rating to a “buy” rating in a report on Tuesday, June 26th. Zacks Investment Research raised EXACT Sciences from a “sell” rating to a “hold” rating in a report on Monday, July 2nd. Robert W. Baird raised their price target on EXACT Sciences from $66.00 to $70.00 and gave the stock an “outperform” rating in a report on Monday, July 9th. Finally, Leerink Swann reissued an “outperform” rating and issued a $76.00 price target (up previously from $67.00) on shares of EXACT Sciences in a report on Wednesday, July 18th.

NASDAQ EXAS traded up $1.01 during mid-day trading on Thursday, reaching $66.78. 33,663 shares of the company’s stock traded hands, compared to its average volume of 2,488,027. The firm has a market cap of $9.69 billion, a PE ratio of -66.65 and a beta of 0.98. The company has a quick ratio of 15.37, a current ratio of 15.79 and a debt-to-equity ratio of 0.87. EXACT Sciences has a 1-year low of $37.36 and a 1-year high of $81.22.

EXACT Sciences (NASDAQ:EXAS) last issued its earnings results on Wednesday, August 1st. The medical research company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.33) by $0.03. The company had revenue of $102.89 million during the quarter, compared to analyst estimates of $104.40 million. EXACT Sciences had a negative return on equity of 20.10% and a negative net margin of 35.24%. The business’s revenue was up 78.5% on a year-over-year basis. During the same quarter last year, the firm earned ($0.27) EPS. On average, analysts anticipate that EXACT Sciences will post -1.41 earnings per share for the current year.

In other EXACT Sciences news, insider Graham Peter Lidgard sold 58,000 shares of EXACT Sciences stock in a transaction on Monday, October 8th. The stock was sold at an average price of $69.36, for a total transaction of $4,022,880.00. Following the sale, the insider now owns 204,684 shares of the company’s stock, valued at approximately $14,196,882.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider D Scott Coward sold 2,190 shares of EXACT Sciences stock in a transaction on Monday, October 1st. The shares were sold at an average price of $79.51, for a total value of $174,126.90. The disclosure for this sale can be found here. In the last three months, insiders sold 75,069 shares of company stock worth $5,102,545. Company insiders own 3.20% of the company’s stock.

A number of institutional investors have recently made changes to their positions in EXAS. Quantbot Technologies LP bought a new stake in EXACT Sciences during the 1st quarter valued at $135,000. Cornerstone Wealth Management LLC bought a new stake in EXACT Sciences during the 2nd quarter valued at $182,000. Hartford Investment Management Co. bought a new stake in EXACT Sciences during the 2nd quarter valued at $202,000. Fulton Bank N.A. bought a new stake in EXACT Sciences during the 3rd quarter valued at $208,000. Finally, Alps Advisors Inc. bought a new stake in EXACT Sciences during the 2nd quarter valued at $210,000. 86.39% of the stock is currently owned by hedge funds and other institutional investors.

EXACT Sciences Company Profile

Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer.

Recommended Story: What Is An Exchange-Traded Fund (ETF)?

Analyst Recommendations for EXACT Sciences (NASDAQ:EXAS)

Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.